James J Chamberlain1, Rita Rastogi Kalyani1, Sandra Leal1, Andrew S Rhinehart1, Jay H Shubrook1, Neil Skolnik1, William H Herman1. 1. From St. Mark's Hospital and St. Mark's Diabetes Center, Salt Lake City, Utah; Johns Hopkins University, Baltimore, Maryland; SinfoníaRx, Tucson, Arizona; Glytec, Marco Island, Florida; Touro University College of Osteopathic Medicine, Vallejo, California; Abington Memorial Hospital, Jenkintown, Pennsylvania; and University of Michigan, Ann Arbor, Michigan.
Abstract
DESCRIPTION: The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. METHODS: For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence. The committee rated the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards of Care were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. RECOMMENDATION: This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.
DESCRIPTION: The American Diabetes Association (ADA) annually updates Standards of Medical Care in Diabetes to provide clinicians, patients, researchers, payers, and other interested parties with evidence-based recommendations for the diagnosis and management of patients with diabetes. METHODS: For the 2017 Standards of Care, the ADA Professional Practice Committee did MEDLINE searches from 1 January 2016 to November 2016 to add, clarify, or revise recommendations on the basis of new evidence. The committee rated the recommendations as A, B, or C, depending on the quality of evidence, or E for expert consensus or clinical experience. The Standards of Care were reviewed and approved by the Executive Committee of the ADA Board of Directors, which includes health care professionals, scientists, and laypersons. Feedback from the larger clinical community informed revisions. RECOMMENDATION: This synopsis focuses on recommendations from the 2017 Standards of Care about monitoring and pharmacologic approaches to glycemic management for type 1 diabetes.
Authors: S L Ferrari; B Abrahamsen; N Napoli; K Akesson; M Chandran; R Eastell; G El-Hajj Fuleihan; R Josse; D L Kendler; M Kraenzlin; A Suzuki; D D Pierroz; A V Schwartz; W D Leslie Journal: Osteoporos Int Date: 2018-07-31 Impact factor: 4.507